HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation $(TMS.AU)$.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.